. SEC Investigating Cassava Sciences, Developer of Experimental Alzheimer’s Drug « JO LEE MAGAZINE

Wall Street Journal – The Securities and Exchange Commission is investigating claims that Cassava Sciences Inc., the sixth-best performing U.S. stock this year, manipulated research results of its experimental Alzheimer’s drug, according to people familiar with the matter.

Cassava disclosed Monday in a securities filing that it is cooperating with government investigations…

More at Wall Street Journal

Comments are closed.